Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 18.67% is 116% above its 5-year average of 8.64%, near the low end of its 5-year range (0.06%–95.15%).
As of the fiscal period ended Tuesday, June 30, 2026. 21.75% above its 12-month average of 15.33%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 18.67%.
DEBT TO ASSETS RATIO
18.67%
DEBT TO ASSETS RATIO AVG TTM
15.33%
DEBT TO ASSETS RATIO AVG 3Y
10.56%
DEBT TO ASSETS RATIO AVG 5Y
8.64%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+21.75%
CURRENT VS 3Y AVG
+76.81%
CURRENT VS 5Y AVG
+116.15%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+20643.74%
vs the sector median at left
Caribou Biosciences, Inc.
Market Cap
$112.57M
Debt to Assets Ratio
18.67%
TTM Avg
15.33%
3Y Avg
10.56%
5Y Avg
8.64%
Market Cap
$112.73M
Debt to Assets Ratio
0.21%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.61M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$113.97M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.77M
Debt to Assets Ratio
0.64%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.27M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$115.29M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.07M
Debt to Assets Ratio
0.65%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | $112.57M | 18.67% | 15.33% | 10.56% | 8.64% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.73M | 0.21% | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | 0.09% | N/A | N/A | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $111.61M | 0.01% | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $113.97M | 0.09% | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.77M | 0.64% | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $110.27M | 0.09% | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $115.29M | 0.00% | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.07M | 0.65% | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $108.18M | 0.07% | N/A | N/A | N/A |
Debt/Assets
18.7%
Debt/Equity
0.27
Current Ratio
6.49
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 18.67% |
| 2026-03-31 | 18.08% |
| 2025-12-31 | 15.16% |
| 2025-09-30 | 13.06% |
| 2025-06-30 | 11.70% |
| 2025-03-31 | 9.58% |
| 2024-12-31 | 8.45% |
| 2024-09-30 | 7.74% |
| 2024-06-30 | 7.67% |
| 2024-03-31 | 7.09% |
| 2023-12-31 | 6.27% |
| 2023-09-30 | 6.00% |
| 2023-06-30 | 7.79% |
| 2023-03-31 | 7.89% |
| 2022-12-31 | 7.42% |
| 2022-09-30 | 6.99% |
| 2022-06-30 | 6.64% |
| 2022-03-31 | 6.29% |
| 2021-12-31 | 0.06% |
| 2021-09-30 | 0.19% |
| 2021-06-30 | 95.15% |
| 2021-03-31 | 0.94% |
| 2020-12-31 | 4.38% |
